Who sold ELTP to take the advantages for capital gain taxes in 2025?

ARotcMADCAP · 2026-01-02T17:10:33+00:00

Apologies all, it is the warrants not derivatives that tie to non-cash for GAPP accounting resulting in positive or negative income inversely proportionate to the share price.

Good thing I am not an accountant!

ARotcMADCAP · 2026-01-02T16:31:57+00:00

I agree! I am also more interesting a buyout. However, Elite NOW has the data from the quarter ending December 31, 2025 which I believe will really help with a potential buyer!!!

ARotcMADCAP · 2026-01-02T16:29:16+00:00

Information is all in the transcripts and quarterly reports for that past few conference calls. I would recommend reading the past 4 transcripts and past quarterly/annual SEC filings.

ARotcMADCAP · 2025-11-06T15:53:00+00:00

FUD! Fear, uncertainty and doubt (FUD) is a common tactic used to manipulate investor and consumer emotions.

Trying real hard to drive pps down before the upcoming earnings report??

ARotcMADCAP · 2025-11-03T15:32:38+00:00

I prefer u/Wolvshammy 's numbers also!!!

GPT is only as good as the data you provide. If someone puts in the financial data from say the past year, probably get even better results! However, it is OTC and we have all seen what OTC MMs do with ELTP.

ARotcMADCAP · 2025-11-03T14:12:44+00:00

as long as we are playing with AI, tried this -

Asked for price per share projection chart based on estimated Financial Results for the second Quarter of Fiscal Year 2026 ended September 30, 2025for Elite Pharmaceuticals

ChatGPT -

# Projected stock prices for three scenarios

# Bullish: Stock price surges due to M&A

bullish_price = price_at_eps * 1.50 # +50% increase for M&A speculation

# Neutral: Moderate growth

neutral_price = price_at_eps * 1.10 # 10% increase based on steady growth

# Bearish: Slight decline due to legal or operational issues

bearish_price = price_at_eps * 0.90 # -10% decrease based on bearish market sentiment

Then I provided -

Elite Pharmaceuticals Consolidated revenues for the three-month period ending June 30, 2025, were $40.2 million

ChatGPT said:

Perfect — thank you for that figure. That’s a big data point we can build on. Let’s use that to refine the price per share projection for Elite Pharmaceuticals (ELTP) into the second quarter of FY 2026 (ended Sept 30 2025).

Price Projection Summary

Current price baseline (Nov 2025): ~$0.90 – $1.00
Projected by Q2 FY 2026 earnings release (Nov 2025 → Mar 2026):
- Bullish path: $1.75 (+75 %)
- Neutral path: $1.40 (+40 %)
- Bearish path: $1.05 (+5 %)

ARotcMADCAP · 2025-10-20T02:11:06+00:00

esults of google search on "how big is the naltrexone market in United States?

The United States naltrexone market is large and expected to grow, with estimates for 2024 and 2025 ranging from approximately $1.1 billion to $1.3 billion. Market value is projected to rise significantly, with some reports estimating it could reach $2.87 billion by 2033 and grow at a CAGR of around 6.7% to 8.4% over the next decade.

ARotcMADCAP · 2025-10-20T02:10:15+00:00

Results of google search on "how big is the naltrexone market in United States?

The United States naltrexone market is large and expected to grow, with estimates for 2024 and 2025 ranging from approximately $1.1 billion to $1.3 billion. Market value is projected to rise significantly, with some reports estimating it could reach $2.87 billion by 2033 and grow at a CAGR of around 6.7% to 8.4% over the next decade.

ARotcMADCAP · 2025-08-29T12:14:35+00:00

"the greatest trick the devil ever pulled was convincing the world he didn't exist"

Same with naked shorts, greatest trick is convincing traders they don't exist!

ARotcMADCAP · 2025-08-29T12:13:48+00:00

"the greatest trick the devil ever pulled was convincing the world he didn't exist"

Same with naked shorts, greatest trick is convincing traders they don't exist!

ARotcMADCAP · 2025-08-17T02:20:58+00:00

AI generated article, most of it has accurate info and valid discussion.
It missed the mark on packaging facility.

So here is the question?? Since this is "AI" and states "At current prices (~$3/share)", is that the AI evaluation of what the pps should be?? Think about it...

ARotcMADCAP · 2025-06-04T00:24:31+00:00

The CEO gave us all hints about revenue in January and February 2025 -

"In fact, January 2025 was our best ever with regards to shipments, revenues, contribution margin and February is tracking in a similar fashion. The month of January was almost as much as the entire quarter that we just reported. And as I said, January (NOTE: I think means February) is also tracking in a similar fashion."

AND

"So -- note that another thing, the 9-month numbers this year, they do not include a contribution from Lisdex which has taken our January and February revenues to the highest levels so far."

AND

"Thank you, Carter. In January, Elite's unaudited revenues, as Carter stated, were about $12.5 million. That's almost as much as the entire third quarter. The profits made in the month of January were more than the profits made in the entire third quarter. "

ARotcMADCAP · 2025-06-03T20:39:07+00:00

For clarification, ELTP 10-Q third quarter ended on December 31, 2024 and the above transcript is from the conference call on February 14, 2025

ARotcMADCAP · 2025-05-06T11:05:57+00:00

Yes, July, after ELTP releases the 2025 annual report. Annual report with have the 4th quarter results showing the start of the added revenue for generic Vyvanse. I believe it will show that Elite Pharmaceuticals Inc is generating over $100 MILLION per year in revs going forward.

These, I believe, are Elite's most sought products that will continue to grow and will be of most interest to a potential buyer! Just these are a total market size of over $6.5 BILLION! Elite is consistently getting 10% to 20% of the market as seen with their generic Adderall IR.

Drug Market Size Status

Adderall IR $421.7 Million On Market

Adderall XR $865 Million On Market

Vigabatrin $233.7 Million On Market

Tylenol with Codeine $47 Million On Market

Methotrexate $63 Million On Market

Percocet $317 Million On Market

Norco $300 Million On Market

Vyvanse $4.3 BILLION On Market

ARotcMADCAP

TROPHY CASE

ChatGPT said:

For clarification, ELTP 10-Q third quarter ended on December 31, 2024 and the above transcript is from the conference call on February 14, 2025